Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myriad Genetics Inc.

www.myriad.com

Latest From Myriad Genetics Inc.

AZ/Merck & Co' s Lynparza Gets US Approval For Prostate Cancer

Lynparza has received the green light from the FDA for advanced prostate cancer, its fourth tumor type, and while it may not be the first PARP inhibitor to be approved for this indication, analysts are expecting the drug to lead the class.

Cancer Approvals

Decade In Review: Biopharma's Shifting Legal Landscape

Emergence of the inter partes review process dramatically changed the patent dispute arena.  The decade also brought biosimilar litigation, generic price-fixing complaints, opioid lawsuits and new government investigations and antitrust actions.

Legal Issues Biosimilars

Global Approvals Snapshot: October 2019

October’s approvals include the US FDA approval of Myriad’s myChoice CDx companion diagnostic for GlaxoSmithKline’s ovarian cancer drug and the approval or Medtronic’s Valiant Navion thoracic stent graft system in Japan.

Approvals Innovation

AML Contender Quizartinib Gains First Approval, In Japan

Japan grants first approval worldwide for Daiichi Sankyo's oral FLT3 inhibitor, marking progress for Japanese firm's global oncology ambitions.

Japan Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Gynecological, Urological
  • Immune Disorders
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Myriad Genetics Inc.
  • Senior Management
  • Mark C Capone, Pres. & CEO
    R. Bryan Riggsbee, CFO
    Jerry H Lanchbury, PhD, CSO
    Mark H Pollack, MD, CMO
    Rishi Kacker, CTO
    Bryan M Dechairo, PhD, EVP, Clinical Dev.
  • Contact Info
  • Myriad Genetics Inc.
    Phone: (801) 584-3600
    320 Wakara Way
    Salt Lake City, UT 84108
    USA
UsernamePublicRestriction

Register